Risks and benefits of dietary isoflavones for cancer

被引:129
|
作者
Andres, Susanne [1 ]
Abraham, Klaus [1 ]
Appel, Klaus Erich [1 ]
Lampen, Alfonso [1 ]
机构
[1] Fed Inst Risk Assessment, Dept Food Safety, D-14195 Berlin, Germany
关键词
Breast cancer; carcinogenicity; daidzein; equol; estradiol; estrogen receptor; genistein; phytoestrogens; prostate cancer; red clover; soy; tumor; ESTROGEN-RECEPTOR-BETA; INSULIN-LIKE-GROWTH; HORMONE REPLACEMENT THERAPY; FACTOR-KAPPA-B; SOY PROTEIN ISOLATE; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; HUMAN PROSTATE-CANCER; 7,12-DIMETHYLBENZ(A)ANTHRACENE-INDUCED MAMMARY-TUMORS; URINARY PHYTOESTROGEN EXCRETION;
D O I
10.3109/10408444.2010.541900
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
A high intake of fruits and vegetables is associated with a lower risk of cancer. In this context, considerable attention is paid to Asian populations who consume high amounts of soy and soy-derived isoflavones, and have a lower risk for several cancer types such as breast and prostate cancers than populations in Western countries. Hence, interest focuses on soyfoods, soy products, and soy ingredients such as isoflavones with regard to their possible beneficial effects that were observed in numerous experiments and studies. The outcomes of the studies are not always conclusive, are often contradictory depending on the experimental conditions, and are, therefore, difficult to interpret. Isoflavone research revealed not only beneficial but also adverse effects, for instance, on the reproductive system. This is also the case with tumor-promoting effects on, for example, breast tissue. Isoflavone extracts and supplements are often used for the treatment of menopausal symptoms and for the prevention of age-associated conditions such as cardiovascular diseases and osteoporosis in postmenopausal women. In relation to this, questions about the effectiveness and safety of isoflavones have to be clarified. Moreover, there are concerns about the maternal consumption of isoflavones due to the development of leukemia in infants. In contrast, men may benefit from the intake of isoflavones with regard to reducing the risk of prostate cancer. Therefore, this review examines the risks but also the benefits of isoflavones with regard to various kinds of cancer, which can be derived from animal and human studies as well as from in vitro experiments.
引用
收藏
页码:463 / 506
页数:44
相关论文
共 50 条
  • [21] Benefits and Risks of Breast Cancer Screening
    Woeckela, Achim
    Janni, Wolfgang
    Porzsolt, Franz
    Schmutzler, Rita
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 21 - 28
  • [22] Benefits and Risks of Skin Cancer Screening
    Breitbart, Eckhard W.
    Choudhury, Kohelia
    Anders, Markus P.
    Volkmer, Beate
    Greinert, Ruediger
    Katalinic, Alexander
    Tacke, Juergen
    Keilholz, Ulrich
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 38 - 47
  • [23] THE RISKS AND BENEFITS OF CORTICOSTEROIDS IN ADVANCED CANCER
    TWYCROSS, R
    [J]. DRUG SAFETY, 1994, 11 (03) : 163 - 178
  • [24] Benefits and Risks of Colorectal Cancer Screening
    Riemann, Juergen F.
    Schroeder, Carsten
    Kallenbach, Maria
    Giersiepen, Klaus
    Schmoll, Hans-Joachim
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 11 - 20
  • [25] Alcohol and cancer: benefits in addition to risks?
    Boffetta, P
    [J]. LANCET ONCOLOGY, 2005, 6 (07): : 443 - 444
  • [26] Prostate cancer:: risks and benefits of screening
    Roemeling, S
    Schröder, FH
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (01): : 4 - 5
  • [27] Risks And Benefits Of Breast Cancer Screening
    Arleo, Elizabeth Kagan
    [J]. HEALTH AFFAIRS, 2016, 35 (03)
  • [28] Prostate cancer: risks and benefits of screening
    Stijn Roemeling
    Fritz H Schröder
    [J]. Nature Clinical Practice Urology, 2006, 3 : 4 - 5
  • [29] Cancer clinical trials: Risks and benefits
    Murphy, SB
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (09) : 564 - 567
  • [30] RISKS AND BENEFITS OF RETINOIDS IN THE CHEMOPREVENTION OF CANCER
    DEPALO, G
    FORMELLI, F
    [J]. DRUG SAFETY, 1995, 13 (04) : 245 - 256